Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. Byers LA, et al. Among authors: bearss dj. Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22. Clin Cancer Res. 2013. PMID: 23091115 Free PMC article.
Targeting Axl and Mer kinases in cancer.
Verma A, Warner SL, Vankayalapati H, Bearss DJ, Sharma S. Verma A, et al. Among authors: bearss dj. Mol Cancer Ther. 2011 Oct;10(10):1763-73. doi: 10.1158/1535-7163.MCT-11-0116. Epub 2011 Sep 20. Mol Cancer Ther. 2011. PMID: 21933973 Review.
Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
Taverna JA, Hung CN, DeArmond DT, Chen M, Lin CL, Osmulski PA, Gaczynska ME, Wang CM, Lucio ND, Chou CW, Chen CL, Nazarullah A, Lampkin SR, Qiu L, Bearss DJ, Warner S, Whatcott CJ, Mouritsen L, Wade M, Weitman S, Mesa RA, Kirma NB, Chao WT, Huang TH. Taverna JA, et al. Among authors: bearss dj. Cancer Res. 2020 Apr 1;80(7):1551-1563. doi: 10.1158/0008-5472.CAN-19-3183. Epub 2020 Jan 28. Cancer Res. 2020. PMID: 31992541 Free PMC article.
Targeting Aurora-2 kinase in cancer.
Warner SL, Bearss DJ, Han H, Von Hoff DD. Warner SL, et al. Among authors: bearss dj. Mol Cancer Ther. 2003 Jun;2(6):589-95. Mol Cancer Ther. 2003. PMID: 12813139 Review.
A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.
Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, Albertson DJ, Call LT, Bearss JJ, Tripp S, Liu T, Stephens BJ, Mollard A, Warner SL, Bearss DJ, Kanner SB. Foulks JM, et al. Among authors: bearss dj, bearss jj. Neoplasia. 2014 May;16(5):403-12. doi: 10.1016/j.neo.2014.05.004. Epub 2014 Jun 18. Neoplasia. 2014. PMID: 24953177 Free PMC article.
77 results